Anticardiolipin Antibodies by an Enzyme-Linked Immunosorbent Assay : Fundamental Studies on the Conditions for Antigen-Application and Specificity of the Assay
-
- ICHIKAWA Yukinobu
- Department of Internal Medicine, School of Medicine, Tokai University
-
- KOBAYASHI Nobumasa
- Blood Transfusion Service Center
-
- KAWADA Tsutomu
- Section of Hematology
-
- MORITA Kazuyuki
- Department of Internal Medicine, School of Medicine, Tokai University
-
- TOKUNAGA Masahito
- Department of Internal Medicine, School of Medicine, Tokai University
-
- UCHIYAMA Mitsuaki
- Department of Internal Medicine, School of Medicine, Tokai University
-
- SHIMIZU Hiroaki
- Department of Internal Medicine, School of Medicine, Tokai University
-
- MORIUCHI Junko
- Department of Internal Medicine, School of Medicine, Tokai University
-
- TAKAYA Masatoshi
- Department of Internal Medicine, School of Medicine, Tokai University
-
- WATANABE Katsuto
- Blood Transfusion Service Center
-
- ARIMORI Shigeru
- Department of Internal Medicine, School of Medicine, Tokai University
この論文をさがす
抄録
We have established an enzyme-linked immunosorbent assay (ELISA) for anticardiolipin antibodies (aCL) using standard sera obtained from the Rayne Institute, St. Thomas' Hospital (London, U.K.). In this study, we compared several fundamental requirements for the assay with the standard assay as a reference, such as conditions for antigen application and test samples using our patients' samples. In addition, the specificity of our assay and cross-reactivities of aCL were also evaluated. In the standard assay, the concentration of antigen was optimal in the range of 30-100μg/ml. The antigen-coating temperature was optimal at 4℃ for 16 hours. The method based on rapid evaporation of CL-ethanol solution can be used instead of the standard method. On the other hand, there was no significant difference in the results between physical conditions of the antigen (CL-ethanol solution vs. CL-micelles), between washing solutions (saline vs. PBS containing 0.05% Tween-20) and between test samples (sera vs. plasma). The aCL activity in our patients' samples was almost completely inhibited by pre-incubation of sera with either CL or phospholipid reagent for activated partial thromboplastin time (APTT). Interestingly, the aCL activity of the lupus anticoagulant was negative, but aCL-positive samples were also absorbed by the reagent for APTT. No inhibition of the aCL activity, however, was observed when patients' sera were preincubated with ss-DNA.
収録刊行物
-
- Tokai journal of experimental and clinical medicine
-
Tokai journal of experimental and clinical medicine 14 (2), 103-112, 1989-04
東海大学
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1574231876711680896
-
- NII論文ID
- 110004700534
-
- NII書誌ID
- AA00863975
-
- ISSN
- 03850005
-
- 本文言語コード
- en
-
- データソース種別
-
- CiNii Articles